{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"92","upperLimit":"100","value":"100"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"100","value":"99.1"}]}],"title":"28 days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"64","upperLimit":"100","value":"100"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"100","value":"100"}]}],"title":"56 days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"43","upperLimit":"100","value":"100"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"100","value":"100"}]}],"title":"100 days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.2","upperLimit":"100","value":"100"},{"groupId":"OG001","lowerLimit":"43.9","upperLimit":"100","value":"100"}]}],"title":"180 days"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"79.4","upperLimit":"100","value":"100"},{"groupId":"OG001","lowerLimit":"83.2","upperLimit":"100","value":"100"}]}],"title":"365 days"}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"Peripheral blood chimerism (% of donor chimerism) in whole blood (unsorted). The degree of donor chimerism will be summarized using descriptive statistics.","dispersionType":"Full Range","groups":[{"description":"Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan","id":"OG000","title":"Myeloablative Conditioning (MAC)"},{"description":"Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation","id":"OG001","title":"Reduced Intensity Conditioning (RIC)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"28 days, 56 days, 100 days, 180 days, and 365 days post-transplant","title":"Donor Chimerism","type":"SECONDARY","unitOfMeasure":"percentage of donor chimerism"}